Direct Acting Agents in Hepatitis C Patients (HEPCTURKEY)

Fehmi Tabak

Status: Completed

Conditions: Hepatitis C Recurrent; Hepatitis C; Hepatitis C Relapse

Study type: Observational

Funder types: Other

Identifiers

NCT03145844

HEPCTURKEY

Details and patient eligibility

About

This study is a retrospective study conducted at 36 sites. Planned target patient number is 1000.

Full description

Approximately 36 centers will be included in Turkey. Centers will be selected from clinics of infection and clinical microbiology. The inclusion of 1000 patients was targeted. All data will be retrospectively collected from the medical records of the patients. Patient visit is not necessary.

Enrollment: 2,700 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who used direct acting agents for Hepatitis C

Exclusion criteria

• Patients younger then 18 years

Trial design

2,700 participants in 1 patient group

Direct Acting Agents

Description:

No Intervention